What is the 13F Pro Quality Score for TECX?

13F Pro ranks Tectonic Therapeutic, Inc. (TECX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TECX's current score at https://13fpro.ai/research/TECX (free sign-up required for the full ranking).

Which hedge funds own the most TECX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TECX include FMR, TCG Crossover Management,, abrdn plc. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/TECX as soon as new 13F filings post.

Where does 13F Pro source TECX data?

All Tectonic Therapeutic, Inc. fundamentals and ownership data come directly from SEC EDGAR. Tectonic Therapeutic, Inc. files with the SEC under CIK 1681087. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TECX in?

Tectonic Therapeutic, Inc. (TECX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TECX research updated on 13F Pro?

TECX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Tectonic Therapeutic, Inc.(TECX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1681087 TECX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

TECX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Tectonic Therapeutic, Inc. (TECX), a Healthcare sector company. TECX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Tectonic Therapeutic, Inc. reports net income of $-25.2M, free cash flow of $-18.4M. Top institutional holders of TECX by reported 13-F value include FMR, TCG Crossover Management,, abrdn plc, based on the most recent SEC filings. TECX trades on the Nasdaq exchange and files with the SEC under CIK 1681087. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TECX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tectonic Therapeutic, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-25.2M

Free Cash Flow

Q1 2026

$-18.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+99.8% YoY

$-74.2MFY 2025

FY21 $-119.1MFY22 $-105.9MFY23 $-42.82BFY25 $-74.2M

Operating Income

-88.2% YoY

$-84.0MFY 2025

FY21 $-118.8MFY22 $-105.4MFY23 $-44.6MFY25 $-84.0M

EPS (Diluted)

-283.9% YoY

$-4.05FY 2025

FY21 $-0.09FY22 $-0.08FY23 $-1.05FY25 $-4.05

Total Assets

+562.5% YoY

$261.0MFY 2025

FY21 $203.8MFY22 $103.9MFY23 $39.4MFY25 $261.0M

Total Debt

—FY 2025

FY21 $15.0MFY22 $15.0MFY23 —FY25 —

Op. Cash Flow

-47.7% YoY

$-60.1MFY 2025

FY21 $-98.0MFY22 $-97.2MFY23 $-40.7MFY25 $-60.1M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2019	FY 2017
Net Income	$-74.2M +99.8%	$-42.82B -40341.0%	$-105.9M +11.1%	$-119.1M -63.3%	$-73.0M -291.3%	$-18.6M
Operating Income	$-84.0M -88.2%	$-44.6M +57.7%	$-105.4M +11.3%	$-118.8M -56.8%	$-75.8M -312.3%	$-18.4M
EPS (Diluted)	$-4.05 -283.9%	$-1.05 -1295.5%	$-0.08 +13.0%	$-0.09	—	—
Total Assets	$261.0M +562.5%	$39.4M -62.1%	$103.9M -49.0%	$203.8M +1.7%	$200.5M +2755.5%	$7.0M
Total Debt	—	—	$15.0M +0.0%	$15.0M	—	—
Operating Cash Flow	$-60.1M -47.7%	$-40.7M +58.2%	$-97.2M +0.8%	$-98.0M -44.9%	$-67.7M -313.1%	$-16.4M

AI Insight: TECX Financial Trends

Tectonic shows deteriorating burn rate with net losses widening to $25M in Q1 2026 from $12M in Q4 2024, while equity base declines consistently.

• Net losses worsened from $12M in Q4 2024 to $25M in Q1 2026, representing a 108% increase.

• Operating losses expanded from $14M in Q4 2024 to $27M in Q1 2026.

• Equity declined steadily from $301M in Q1 2025 to $230M in Q1 2026.

⚠ Operating cash outflows remain elevated at $18M in Q1 2026 despite quarterly volatility.

⚠ Burn rate acceleration threatens runway with $71M equity decline over past year.

AI Insight: TECX Ratio Trends

ROIC deteriorated sharply to -47.4% in Q1 2026 from -24.3% in Q1 2025, erasing prior year's recovery trajectory.

• ROE worsened from -21.1% in Q1 2025 to -43.8% in Q1 2026, marking significant deterioration in profitability.

• ROIC declined from -24.3% in Q1 2025 to -47.4% in Q1 2026, indicating weakening capital efficiency.

• ROA dropped from -20.2% in Q1 2025 to -40.9% in Q1 2026, reflecting declining asset utilization.

⚠ All profitability metrics remain deeply negative with Q1 2026 showing worst performance since Q3 2024.

⚠ Recovery trend from Q1 2025 lows has completely reversed, suggesting operational challenges persist.

Get alerted when TECX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Tectonic Therapeutic, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TECX

FMR LLC
$87.1M2,816,494 sh
TCG Crossover Management, LLC
$37.2M1,204,891 sh
abrdn plc
$35.3M1,141,824 sh
BlackRock, Inc.
$26.6M860,352 sh
BRAIDWELL LP
$26.2M847,151 sh
First Light Asset Management, LLC
$20.0M647,743 sh
BAKER BROS. ADVISORS LP
$18.8M607,788 sh
5AM Venture Management, LLC
$18.8M606,660 sh
VANGUARD CAPITAL MANAGEMENT LLC
$14.6M473,532 sh
Vestal Point Capital, LP
$10.1M328,000 sh

Fund	Value	Shares
FMR LLC	$87.1M	2,816,494
TCG Crossover Management, LLC	$37.2M	1,204,891
abrdn plc	$35.3M	1,141,824
BlackRock, Inc.	$26.6M	860,352
BRAIDWELL LP	$26.2M	847,151
First Light Asset Management, LLC	$20.0M	647,743
BAKER BROS. ADVISORS LP	$18.8M	607,788
5AM Venture Management, LLC	$18.8M	606,660
VANGUARD CAPITAL MANAGEMENT LLC	$14.6M	473,532
Vestal Point Capital, LP	$10.1M	328,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TECX on your watchlist

Track score changes the day Tectonic Therapeutic, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TECX a good stock to buy?

13F Pro's AI-powered analysis of Tectonic Therapeutic, Inc. (TECX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TECX are available on the TECX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TECX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TECX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Tectonic Therapeutic, Inc.'s investment landscape.